HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease - ScienceDirect
DailyMed - HUMIRA- adalimumab kit HUMIRA- adalimumab injection, solution - Inergency
Characterisation of the glycosylation of Humira (adalimumab) and Erbitux (Cetuximab) by high resolution mass spectrometry | Quality Assistance
Latest set of Humira commercials debuts to mixed patient response - MM+M - Medical Marketing and Media
Adalimumab: Uses, Interactions, Mechanism of Action | DrugBank Online
FDA Grants Interchangeable Status to Humira Biosimilar, but Certain Factors May Hamper Its, Other Adalimumabs' Uptake - MMIT Network
Frontiers | Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
3 Adalimumab
RCSB PDB - 6CR1: adalimumab EFab
Figure 5 from Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases | Semantic Scholar
AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
Genotyping by Sequencing for Crop Improvement: Sonah, Humira, Goyal, Vinod, Shivaraj, S. M., Deshmukh, Rupesh K.: 9781119745655: Books - Amazon.ca
AbbVie 2017: Humira, And What's Next – PharmaLive
B. Space-filling models of the monoclonal antibody Adalimumab (Humira)... | Download Scientific Diagram
Design of a stable cell line producing a recombinant monoclonal anti-TNFα antibody based on a CHO cell line | SpringerPlus | Full Text
A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis | Scientific Reports
Adalimumab competition to intensify in US due to launch of Humira biosimilars < Pharma < Article - KBR
Frontiers | Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial
Physicochemical and Functional Characterization of HS016, a Biosimilar of Adalimumab (Humira) - Journal of Pharmaceutical Sciences
HUMIRA (adalimumab)
Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study - ScienceDirect
Biomolecules | Free Full-Text | Anti-TNF Alpha Antibody Humira with pH-dependent Binding Characteristics: A constant-pH Molecular Dynamics, Gaussian Accelerated Molecular Dynamics, and In Vitro Study
Peptide Mapping LC-MS/MS Analysis Workflow for Adalimumab
